MENU
+Compare
RNA
Stock ticker: NASDAQ
AS OF
Apr 1, 11:44 AM (EDT)
Price
$28.67
Change
-$0.85 (-2.88%)
Capitalization
3.8B

RNA Avidity Biosciences Forecast, Technical & Fundamental Analysis

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs... Show more

RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RNA with price predictions
Mar 31, 2025

RNA in upward trend: 10-day moving average broke above 50-day moving average on March 19, 2025

The 10-day moving average for RNA crossed bullishly above the 50-day moving average on March 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where RNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

RNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RNA as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RNA turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

RNA moved below its 50-day moving average on March 31, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RNA entered a downward trend on March 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.491) is normal, around the industry mean (13.677). P/E Ratio (0.000) is within average values for comparable stocks, (64.969). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.870). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (303.030) is also within normal values, averaging (255.565).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RNA is expected to report earnings to rise 9.41% to -87 cents per share on May 13

Avidity Biosciences RNA Stock Earnings Reports
Q1'25
Est.
$-0.88
Q4'24
Est.
$-0.80
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.19
Q1'24
Beat
by $0.02
The last earnings report on February 27 showed earnings per share of -80 cents, meeting the estimate of -80 cents. With 132.51K shares outstanding, the current market capitalization sits at 3.80B.
A.I. Advisor
published General Information

General Information

a company which engages in the research and development of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 401-7900
Employees
253
Web
https://www.aviditybiosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GLTR129.471.37
+1.07%
abrdn Physical PrecMtlBsk Shrs ETF
UTWO48.470.03
+0.05%
US Treasury 2 Year Note ETF
AUDUSD0.63N/A
N/A
Australian Dollar - United States Dollar
PSCJ25.80N/A
N/A
Pacer Swan SOS Conservative (July) ETF
BTA9.69-0.02
-0.21%
Blackrock Long-Term Municipal Advantage Trust

RNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-6.58%
DYN - RNA
45%
Loosely correlated
-8.65%
ACLX - RNA
44%
Loosely correlated
-3.47%
CRNX - RNA
42%
Loosely correlated
-3.43%
RYTM - RNA
42%
Loosely correlated
-3.34%
RVMD - RNA
41%
Loosely correlated
-5.33%
More